COMPANY RESEARCHObsidian Therapeutics, Inc.
Obsidian Therapeutics is a publicly traded biotechnology company developing engineered tumor infiltrating lymphocyte therapies for people with solid tumors. Its research uses regulated protein activity to influence selected functions of modified immune cells, with a focus on investigational cancer treatments. Obsidian became publicly traded in 2026 through a corporate transaction involving Galera Therapeutics. Its current issuer identity and earlier corporate history should be understood together, rather than as separate active public companies.
Company at a glance
Corporate information
- Company entity
- Obsidian Therapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://obsidiantx.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Capital Market: OBX
engineered TIL · regulated cell therapy
solid tumors · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Obsidian Therapeutics is a publicly traded biotechnology company developing engineered tumor infiltrating lymphocyte therapies for people with solid tumors. Its research uses regulated protein activity to influence selected functions of modified immune cells, with a focus on investigational cancer treatments. Obsidian became publicly traded in 2026 through a corporate transaction involving Galera Therapeutics. Its current issuer identity and earlier corporate history should be understood together, rather than as separate active public companies.
Business, technology & evidence
- SecuritiesNasdaq Capital Market: OBX
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Obsidian Therapeutics, Inc. ↗Obsidian Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Obsidian Therapeutics, Inc. ↗Obsidian Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Obsidian Therapeutics, Inc. ↗Obsidian Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.